The Proteometer™ will provide FDA guided analytics to pharmaceutical antibody manufactures.
WEST LAFAYETTE, IN – Novilytic, LLC, an Indiana based bio-analytics company that secures lifesaving drugs and medical devices, announces that it has been awarded a Phase II Small Business Innovation Research (SBIR) contract by the National Institute of General Medical Sciences (NIGMS), one of the National Institutes of Health.
The $1.4M Phase II contract will allow Novilytic to continue the research, development, and commercialization of their new Proteometer™. The new instrument technology is being developed for Process R&D Chemists and Process Engineers who need to develop better process quality and control.
“The Proteometer™ represents a truly disruptive technology that will allow process research and manufacturing chemists/engineers to monitor and control antibody growth in process. There is no technology available to do this currently.”, advised Dr. Fred Regnier, CTO and co-founder.
Novilytic is currently focused on the pharmaceutical bioreactor market that produces monoclonal antibodies, one of the most important biopharmaceuticals used to treat many cancers, diseases, and viruses. The market is hampered as these drugs require extensive post-production testing. Until the Proteometer™, no instrument was available to test antibody purity in process, thus releasing that regulatory (FDA) and monetary burden.
“We are very grateful to the NIH and its support of our various developments. This SBIR makes our 6th straight SBIR grant. Initial grants led to the commercialization of patented medical devices. This award signifies our commitment to developing strong technology and patented instruments here in Indiana.”, said Novilytic CEO, Paul Dreier.
The company, who is also launching a Seed Round Funding opportunity, will be opening new laboratories and hiring additional scientists in the coming months.
Through the support of the Purdue Research Foundation and Purdue Foundry, Novilytic will continue to grow in the West Lafayette area.
About Novilytic, LLC
Novilytic is a biochemistry analytics company that secures lifesaving drugs and medical devices. The company is backed by very strong partnerships with large analytical companies, AI leaders, and Pharmaceutical consortiums. Our potency is extended by the Novilytic Team which includes multiple Ph.D. Chemists and Engineers who have helped us secure significant patents and other IP. Our business plan will increase those forces to insure we meet customer, market, and regulatory demands. Learn more at: https://www.novilytic.com/
About the National Institute of General Medical Sciences of the National Institute of Health
The National Institute of General Medical Sciences (NIGMS) supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS-funded scientists investigate how living systems work at a range of levels from molecules and cells to tissues and organs, in research organisms, humans, and populations.
NIGMS is one of the National Institutes of Health (NIH), the principal medical research agency of the Federal Government. NIH is a component of the U.S. Department of Health and Human Services. The above content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”
Learn more at: https://www.nigms.nih.gov/
Inquiries:
Contact: Paul C. Dreier, BSc., MBA / email: pdreier@novilytic.com / telephone: +1.317.752.3116